SRx Health Solutions (NYSE: SRXH) secures NYSE American listing plan

Rhea-AI Filing Summary

SRx Health Solutions, Inc. reports that NYSE American has accepted its plan to regain compliance with listing standards, allowing its common stock to continue trading during a plan period ending July 14, 2026. The company must give NYSE American quarterly updates on its progress toward the plan’s goals.

NYSE American previously notified the company that it fell below the continued listing requirement for stockholders’ equity of $4 million after SRx Health Solutions reported stockholders’ equity of ($45.9) million as of June 30, 2025, along with losses in three of its four most recent fiscal years ended December 31, 2024. The company states that it intends to regain compliance with Section 1003(a)(i) within the plan period.

Positive

• None.

Negative

• Noncompliance with NYSE equity standards: SRx reported stockholders’ equity of ($45.9) million as of June 30, 2025, below the NYSE American $4 million minimum, and its listing is only continued under a plan period through July 14, 2026.

Insights

Equity analyst

NYSE American accepted SRx’s compliance plan, but listing hinges on fixing a deep equity deficit.

SRx Health Solutions has secured NYSE American’s acceptance of its plan to regain compliance, so its shares remain listed during a plan period through July 14, 2026. This buys time, but the plan must address both low stockholders’ equity and a history of losses.

The exchange cited noncompliance with Section 1003(a)(i) because stockholders’ equity was reported at ($45.9) million as of June 30, 2025, far below the $4 million minimum, and the company had losses in three of its four most recent fiscal years ended December 31, 2024. Such negative equity typically reflects cumulative losses exceeding capital.

Continued NYSE American listing now depends on SRx executing the initiatives in its accepted plan and demonstrating improved equity levels during the period ending July 14, 2026. Quarterly updates to the exchange will show whether the company is progressing toward restoring stockholders’ equity to the required threshold.

false 0001471727 0001471727 2026-01-06 2026-01-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): January 6, 2026

SRx Health Solutions, Inc.

(Exact name of Registrant as Specified in its Charter)

Delaware		001-40477		83-4284557
(State or other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

801 US Highway 1

North Palm Beach, Florida 33408

(Address of Principal Executive Offices) (Zip Code)

(Registrant’s Telephone Number, Including Area Code): (212) 896-1254

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value share		SRXH		NYSE American

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On January 6, 2026, SRx Health Solutions, Inc. (the “Company”), received a notice from the NYSE American (“NYSE”), that NYSE has accepted the Company’s plan to regain compliance with Sections 1003(a)(i) and (ii) of the NYSE American Company Guide.

As previously disclosed, NYSE notified the Company on October 14, 2025, that the Company had fallen below the NYSE’s continued listing standard requiring a listed company to have stockholders’ equity of $4 million or more if the listed company has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. With the NYSE’s acceptance of the Company’s plan to regain compliance, the Company’s listing is being continued pursuant to an extension with a targeted completion date of July 14, 2026 (the “Plan Period”). The Company will provide quarterly updates to the NYSE American during the Plan Period on its progress with the goals and initiatives outlined in the plan.

In the notice letter, NYSE American also notified the Company that it was not in compliance with Section 1003(a)(i) of the Company Guide as it reported stockholders’ equity of ($45.9) million as of June 30, 2025, and had losses from continuing operations and/or net losses in three out of its four most recent fiscal years ended December 31, 2024. The Company intends to gain compliance with Section 1003(a)(i) during the Plan Period.

On January 8, 2026, the Company issued a press release announcing the developments disclosed in this report. A copy of the press release is included as an Exhibit 99.1 to this report.

Cautionary Note Regarding Forward-Looking Statements

This Current Report on Form 8-K contains statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Management’s projections and expectations are subject to a number of risks and uncertainties that could cause actual performance to differ materially from that predicted or implied. Forward-looking statements may be identified by the use of words such as “expect,” “anticipate,” “believe,” “estimate,” “potential,” “should” or similar words intended to identify information that is not historical in nature. Forward-looking statements contained herein include, among others, statements concerning management’s expectations about future events and the Company’s operating plans and performance, including levels of consumer, business and economic confidence generally, the regulatory environment, litigation, sales, and the expected benefits of acquisitions, and such statements are based on the current beliefs and expectations of the Company’s management, as applicable, and are subject to known and unknown risks and uncertainties. There are a number of risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. These statements speak only as of the date they are made, and the Company does not intend to update or otherwise revise the forward-looking information to reflect actual results of operations, changes in financial condition, changes in estimates, expectations or assumptions, changes in general economic or industry conditions or other circumstances arising and/or existing since the preparation of this Current Report on Form 8-K or to reflect the occurrence of any unanticipated events. For further information regarding the risks associated with the Company’s business, please refer to the Company’s filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the most recent fiscal year end, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.

Exhibits		Description
99.1		Press Release, dated January 8, 2026.
104		Cover Page Interactive Data File (Embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	SRx Health Solutions, Inc.
	By:	/s/ Carolina Martinez
	Name:	Carolina Martinez
	Title:	Chief Financial Officer

January 8, 2026